RT Book, Section
A1 Menon, Manoj P.
A1 Harrington, Robert D.
A1 Broudy, Virginia C.
A2 Kaushansky, Kenneth
A2 Prchal, Josef T.
A2 Burns, Linda J.
A2 Lichtman, Marshall A.
A2 Levi, Marcel
A2 Linch, David C.
SR Print(0)
ID 1180472349
T1 Hematologic Manifestations of Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome
T2 Williams Hematology, 10e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260464122
LK accessmedicine.mhmedical.com/content.aspx?aid=1180472349
RD 2024/04/19
AB SUMMARYThe  prevalence  of  HIV  in  the  United  States  continues  to  rise  as  a  result  of  the  combined  effects  of  a  declining  HIV  death  rate  and  a  sustained  rate  of  new  infections.  Furthermore,  HIV-infected  patients  on  antiretroviral  therapy  can  expect  to  live  nearly  almost  as  long  as  uninfected  persons  (within  5  years)  providing  ample  time  for  individuals  to  develop  AIDS-associated  and  non–AIDS-associated  hematologic  and  oncologic  conditions.  HIV-infected  individuals  remain  at  increased  risk  of  AIDS-defining  malignancies  such  as  Kaposi  sarcoma,  aggressive  non-Hodgkin  lymphoma,  primary  CNS  lymphoma,  and  invasive  cervical  cancer  and  several  non–AIDS-defining  malignancies,  including  Hodgkin  lymphoma,  as  well  as  anemia  and  thrombocytopenia.  When  individuals  present  with  any  of  these  hematologic  or  malignant  illnesses,  it  should  be  the  standard  of  care  to  obtain  HIV  testing  to  provide  optimal  treatment  for  both  the  presenting  illness  and  the  HIV.